Drug Report History

Return to report

Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.

The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.

Version v6-FR Version v2-FR
Language French French
Date Updated 2021-05-17 2021-03-29
Drug Identification Number 02230540 02230540
Brand name CLINDAMYCIN INJECTION USP CLINDAMYCIN INJECTION USP
Common or Proper name CLINDAMYCIN INJECTION USP CLINDAMYCIN INJECTION USP
Company Name SANDOZ CANADA INCORPORATED SANDOZ CANADA INCORPORATED
Ingredients CLINDAMYCIN CLINDAMYCIN
Strength(s) 150MG 150MG
Dosage form(s) LIQUID LIQUID
Route of administration INTRAMUSCULAR INTRAVENOUS INTRAMUSCULAR INTRAVENOUS INTRAMUSCULAR INTRAVENOUS INTRAMUSCULAR INTRAVENOUS
Packaging size 6ML 10 LVI V2 CA 6ML 10 LVI V2 CA
ATC code J01FF J01FF
ATC description MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS
Reason for shortage Requirements related to complying with good manufacturing practices. Requirements related to complying with good manufacturing practices.
Anticipated start date
Actual start date 2021-03-26 2021-03-26
Estimated end date 2021-06-18 2021-04-30
Actual end date
Shortage status Actual shortage Actual shortage
Tier 3 Status No No
Company comments
Health Canada comments